Corcept Therapeutics(CORT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

CORT Corcept Therapeutics

Market Closed 04-10 16:00:00 EDT

41.91

-0.34

-0.80%

盘后42.14

+0.23+0.55%

19:56 EDT

High42.81	Low41.45	Vol843.28K
Open42.34	D1 Closing42.25	Amplitude3.22%
Mkt Cap4.46B	Tradable Cap3.64B	Total Shares106.37M
T/O35.35M	T/O Rate0.97%	Tradable Shares86.88M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"CORT","market":"US","secType":"STK","nameCN":"Corcept Therapeutics","latestPrice":41.91,"timestamp":1775851200000,"preClose":42.25,"halted":0,"volume":843275,"hourTrading":{"tag":"盘后","latestPrice":42.14,"preClose":41.91,"latestTime":"19:56 EDT","volume":18019,"amount":755329.5453,"timestamp":1775865391930,"change":0.23,"changeRate":0.005488,"amplitude":0.005488},"delay":0,"changeRate":-0.00804733727810659,"floatShares":86875270,"shares":106374020,"eps":0.82,"marketStatus":"Market Closed","change":-0.34,"latestTime":"04-10 16:00:00 EDT","open":42.34,"high":42.81,"low":41.45,"amount":35352656.61565,"amplitude":0.032189,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":0.82,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1776067200000},"marketStatusCode":7,"adr":0,"adrRate":0,"listingDate":1081915200000,"exchange":"NASDAQ","adjPreClose":42.25,"preHourTrading":{"tag":"盘前","latestPrice":42.62,"preClose":42.25,"latestTime":"09:23 EDT","volume":1004,"amount":42790.517148000006,"timestamp":1775827386967,"change":0.37,"changeRate":0.008757,"amplitude":0.000237},"postHourTrading":{"tag":"盘后","latestPrice":42.14,"preClose":41.91,"latestTime":"19:56 EDT","volume":18019,"amount":755329.5453,"timestamp":1775865391930,"change":0.23,"changeRate":0.005488,"amplitude":0.005488},"volumeRatio":0.686259335516652,"impliedVol":0.5202,"impliedVolPercentile":0.268},"requestUrl":"/m/hq/s/CORT","defaultTab":"news","newsList":[{"id":"2626143515","title":"Corcept Therapeutics presents final overall survival data from ROSELLA trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2626143515","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626143515?lang=en_us&edition=fundamental","pubTime":"2026-04-11 04:56","pubTimestamp":1775854568,"startTime":"0","endTime":"0","summary":"Corcept Therapeutics (CORT) presented final overall survival data from its pivotal Phase 3 ROSELLA trial of Lifyorli combined with the chemotherape...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/corcept-therapeutics-presents-final-overall-survival-data-from-rosella-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/corcept-therapeutics-presents-final-overall-survival-data-from-rosella-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0566484027.USD","BK4532","CORT","BK4007","LU1559883803.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626487031","title":"Corcept ROSELLA trial shows Lifyorli plus nab-paclitaxel cuts death risk 35%","url":"https://stock-news.laohu8.com/highlight/detail?id=2626487031","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626487031?lang=en_us&edition=fundamental","pubTime":"2026-04-11 04:45","pubTimestamp":1775853920,"startTime":"0","endTime":"0","summary":"Corcept presented complete overall survival results from Phase 3 ROSELLA trial at SGO 2026, with simultaneous publication in The Lancet.Study showed Lifyorli  with nab-paclitaxel extended survival versus nab-paclitaxel alone in platinum-resistant ovarian cancer.Regimen was added to NCCN Guidelines as a preferred option for platinum-resistant ovarian cancer.FDA cleared Lifyorli in March 2026 for adults with platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer following 1-3 prior systemic regimens.Trial results supported use without a meaningful increase in overall treatment burden versus chemotherapy alone.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260410:nNDL9jqNHm:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","LU1559883803.SGD","BK4532","CORT","LU0566484027.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626314874","title":"Corcept Presents Complete Data From Pivotal Rosella Trial in Sgo Late-Breaker With Simultaneous Publication in the Lancet: Lifyorli™ (Relacorilant) Plus Nab-Paclitaxel Improves Overall Survival in Patients With Platinum-Resistant Ovarian Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2626314874","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626314874?lang=en_us&edition=fundamental","pubTime":"2026-04-11 04:45","pubTimestamp":1775853900,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260410:nTUA62TXY8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0566484027.USD","BK4532","CORT","BK4007","LU1559883803.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626297348","title":"Corcept CDO William Guyer sells 20,000 shares for $819,400","url":"https://stock-news.laohu8.com/highlight/detail?id=2626297348","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626297348?lang=en_us&edition=fundamental","pubTime":"2026-04-09 07:35","pubTimestamp":1775691337,"startTime":"0","endTime":"0","summary":"Corcept Chief Development Officer William Guyer sold 20,000 shares on April 7 at a weighted average price of $40.97.He exercised options for 20,000 shares at $21.65 on same day.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Corcept Therapeutics Incorporated published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 08, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260408:nNDL9N8230:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Corcept CDO William Guyer sells 20,000 shares for $819,400","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","CORT","LU1559883803.SGD","BK4532","LU0566484027.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624579886","title":"Corcept Faces Securities Lawsuits As Relacorilant Story Splits On FDA Outcomes","url":"https://stock-news.laohu8.com/highlight/detail?id=2624579886","media":"Simply Wall St.","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624579886?lang=en_us&edition=fundamental","pubTime":"2026-04-03 19:27","pubTimestamp":1775215639,"startTime":"0","endTime":"0","summary":"Multiple securities fraud lawsuits have been filed against Corcept Therapeutics (NasdaqCM:CORT), alleging the company misled investors about FDA concerns and trial efficacy for relacorilant.\nPlaintiffs claim Corcept did not fully disclose FDA reservations about the adequacy of clinical data before a Complete Response Letter declined approval for a specific indication.\nThe FDA decision was followed by a sharp share price drop and a wave of class action filings from several law firms.\nThe...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cort/corcept-therapeutics/news/corcept-faces-securities-lawsuits-as-relacorilant-story-spli","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cort/corcept-therapeutics/news/corcept-faces-securities-lawsuits-as-relacorilant-story-spli","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU0566484027.USD","BK4588","BK4007","BK4532","LU1559883803.SGD","BK4585","LABU","CORT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624514577","title":"Shareholders Sue Corcept Therapeutics Over Cushing’s Syndrome Drug Claims","url":"https://stock-news.laohu8.com/highlight/detail?id=2624514577","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624514577?lang=en_us&edition=fundamental","pubTime":"2026-04-02 17:40","pubTimestamp":1775122829,"startTime":"0","endTime":"0","summary":"A class action lawsuit was filed against Corcept Therapeutics ($CORT) on February 20, 2026. Plaintiffs -shareholders- in the federal securities cla...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/shareholders-sue-corcept-therapeutics-over-cushings-syndrome-drug-claims?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/shareholders-sue-corcept-therapeutics-over-cushings-syndrome-drug-claims?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","CORT","BK4532","LU1559883803.SGD","LU0566484027.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624579351","title":"MOMENTUM Data Expands Hypercortisolism Opportunity For Corcept Investors","url":"https://stock-news.laohu8.com/highlight/detail?id=2624579351","media":"Simply Wall St.","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624579351?lang=en_us&edition=fundamental","pubTime":"2026-04-02 15:24","pubTimestamp":1775114696,"startTime":"0","endTime":"0","summary":"Corcept Therapeutics (NasdaqCM:CORT) presented new late breaking MOMENTUM trial data at the American College of Cardiology 2026 Annual Scientific Session.\nThe study reported a high prevalence of previously undiagnosed endogenous hypercortisolism in patients with resistant hypertension.\nThe findings suggest a larger pool of patients who might be candidates for therapies that target hypercortisolism.\n\nFor you as a shareholder or potential investor, this update adds an extra layer to the usual...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cort/corcept-therapeutics/news/momentum-data-expands-hypercortisolism-opportunity-for-corce","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cort/corcept-therapeutics/news/momentum-data-expands-hypercortisolism-opportunity-for-corce","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4007","LU1559883803.SGD","BK4211","ISBC","LU0566484027.USD","CORT","BK4532"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623931345","title":"Analysts Are Bullish on Top NA Stocks: Ottobock SE & Co. KGaA (OBCKF), Corcept Therapeutics (CORT)","url":"https://stock-news.laohu8.com/highlight/detail?id=2623931345","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623931345?lang=en_us&edition=fundamental","pubTime":"2026-03-30 21:40","pubTimestamp":1774878044,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the NA sector as 2 analysts just weighed in on Ottobock SE & Co. KGaA (OBCKF) and Corcept Therapeutics (COR...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-top-na-stocks-ottobock-se-co-kgaa-obckf-corcept-therapeutics-cort-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-top-na-stocks-ottobock-se-co-kgaa-obckf-corcept-therapeutics-cort-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0175139822.USD","SG9999002679.SGD","SG9999013486.USD","LU2065171402.SGD","BK4112","SG9999013460.SGD","LU1242518931.SGD","IE0001KFT4U8.USD","LU0516423174.USD","LU1242518857.USD","LU1559883803.SGD","LU0979878070.USD","LU2045819591.USD","LU2065170008.USD","LU2065171311.SGD","BK4548","BK4551","BLSX","LU0823039010.USD","CORT","LU2125910849.SGD","LU0264606111.USD","LU0566484027.USD","SG9999005177.SGD","SG9999014492.USD","LU0072462343.USD","SG9999006266.SGD","LU2177674079.SGD","LU2543165471.USD","SG9999013478.USD","LU0261945553.USD","LU1770036033.HKD","SG9999002620.SGD","SG9999002414.USD","SE","LU2152927971.USD","BK4581","LU0589944569.HKD","LU2008162690.USD","BK4566","BK4085","LU1861220207.SGD","LU1861217088.USD","LU0516422440.USD","BK4535","LU0572939691.SGD","LU0345776255.USD","BK4532","LU0737861269.HKD","BK4588","BLSG","LU0210637038.USD","IE0034224299.USD","IE0031814969.USD","LU0348788117.USD","LU0572940350.SGD","LU0499858602.USD","LU0516422952.EUR","LU0516422366.SGD","LU2238330802.EUR","BK4007","BK4141","LU0289960550.SGD","BK4220","LU0532188223.SGD","LU0499858438.USD","SG9999001135.SGD","SGXZ58947870.SGD","BK4503","SG9999002604.SGD","SG9999002406.SGD","LU0441851309.USD","LU0251143029.SGD","SG9999004360.SGD","LU0048573645.USD","LU0516423091.SGD","LU1048588211.SGD","LU1839390173.USD","BK4585","LU0345775950.USD","LU2065169927.USD","LU2125910500.SGD","LU0823038988.USD","BK4554","IE00BD6J9T35.USD","SG9999014484.SGD","LU2360107671.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623708351","title":"Corcept Therapeutics presents data from Momentum trial at ACC 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2623708351","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623708351?lang=en_us&edition=fundamental","pubTime":"2026-03-29 22:55","pubTimestamp":1774796140,"startTime":"0","endTime":"0","summary":"Corcept Therapeutics (CORT) presented late-breaking data from its Momentum trial examining the prevalence of endogenous hypercortisolism in patient...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/corcept-therapeutics-presents-data-from-momentum-trial-at-acc-2026-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/corcept-therapeutics-presents-data-from-momentum-trial-at-acc-2026-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","CORT","BK4532","LU1559883803.SGD","LU0566484027.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623380224","title":"Corcept MOMENTUM trial finds hypercortisolism in 27.3% of resistant hypertension patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2623380224","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623380224?lang=en_us&edition=fundamental","pubTime":"2026-03-29 02:45","pubTimestamp":1774723525,"startTime":"0","endTime":"0","summary":"Corcept presented late-breaking MOMENTUM trial data at ACC 2026 on endogenous hypercortisolism prevalence in resistant hypertension.Screening of 1,086 patients found 27.3% had hypercortisolism.Results extend Corcept’s earlier CATALYST screening study in difficult-to-control type 2 diabetes, which found 23.8% prevalence in 1,057 patients.High-risk subgroup with HbA1c ≥7.5% on three or more blood pressure medicines showed 32.6% prevalence in MOMENTUM.Data support broader screening for hypercortisolism in hard-to-treat cardiometabolic patients, potentially expanding diagnosis rates relevant to Corcept’s cortisol-modulating drug portfolio.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Corcept Therapeutics Incorporated published the origin","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260328:nNDL4Hr8l0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4532","LU0566484027.USD","LU1559883803.SGD","BK4007","CORT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622808968","title":"Corcept Therapeutics Chief Executive Officer Joseph K. Belanoff disposes of 26,198 common shares; value $1,312,000","url":"https://stock-news.laohu8.com/highlight/detail?id=2622808968","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622808968?lang=en_us&edition=fundamental","pubTime":"2026-03-28 04:28","pubTimestamp":1774643318,"startTime":"0","endTime":"0","summary":"Joseph K. Belanoff, Chief Executive Officer and director at Corcept, reported a sale of 26,198 common shares on March 25, 2026.The shares were sold at a weighted average price of USD 50.07 per share.Following the transaction, 2,918,326 shares were reported as beneficially owned indirectly through a revocable living trust.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Corcept Therapeutics Incorporated published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 27, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260327:nNDL6964xK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Corcept Therapeutics Chief Executive Officer Joseph K. Belanoff disposes of 26,198 common shares; value $1,312,000","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","LU1559883803.SGD","BK4532","LU0566484027.USD","CORT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622868655","title":"Corcept Therapeutics upgraded to Peer Perform from Underperform at Wolfe Research","url":"https://stock-news.laohu8.com/highlight/detail?id=2622868655","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622868655?lang=en_us&edition=fundamental","pubTime":"2026-03-26 20:50","pubTimestamp":1774529458,"startTime":"0","endTime":"0","summary":"Wolfe Research analyst Kalpit Patel upgraded Corcept Therapeutics (CORT) to Peer Perform from Underperform with no price target after the company r...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/corcept-therapeutics-upgraded-to-peer-perform-from-underperform-at-wolfe-research-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/corcept-therapeutics-upgraded-to-peer-perform-from-underperform-at-wolfe-research-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CORT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622854822","title":"Piper Sandler Sticks to Their Buy Rating for Corcept Therapeutics (CORT)","url":"https://stock-news.laohu8.com/highlight/detail?id=2622854822","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622854822?lang=en_us&edition=fundamental","pubTime":"2026-03-26 19:15","pubTimestamp":1774523749,"startTime":"0","endTime":"0","summary":"In a report released today, David Amsellem from Piper Sandler reiterated a Buy rating on Corcept Therapeutics, with a price target of $73.00. Amsel...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/piper-sandler-sticks-to-their-buy-rating-for-corcept-therapeutics-cort-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/piper-sandler-sticks-to-their-buy-rating-for-corcept-therapeutics-cort-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CORT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622001313","title":"Corcept Faces Investor Suit Over Relacorilant NDA Disclosure","url":"https://stock-news.laohu8.com/highlight/detail?id=2622001313","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622001313?lang=en_us&edition=fundamental","pubTime":"2026-03-26 03:10","pubTimestamp":1774465816,"startTime":"0","endTime":"0","summary":"Corcept Therapeutics (CORT) told investors approval was on track through December 2025. Then the company disclosed that the FDA had issued a Comple...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/class-action/corcept-faces-investor-suit-over-relacorilant-nda-disclosure?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/class-action/corcept-faces-investor-suit-over-relacorilant-nda-disclosure?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU1559883803.SGD","LU0566484027.USD","LABU","BK4532","CORT","BK4007","BK4588","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622094710","title":"Corcept Therapeutics Inc: Wholesale Acquisition Cost of a 28-Day Cycle of Lifyorli Therapy Is $37,900","url":"https://stock-news.laohu8.com/highlight/detail?id=2622094710","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622094710?lang=en_us&edition=fundamental","pubTime":"2026-03-26 02:59","pubTimestamp":1774465166,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260325:nFWN40D11F:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CORT","LU1559883803.SGD","BK4532","BK4007","LU0566484027.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622400500","title":"BUZZ-U.S. STOCKS ON THE MOVE-ADMA Biologics, Nanobiotix, DraftKings","url":"https://stock-news.laohu8.com/highlight/detail?id=2622400500","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622400500?lang=en_us&edition=fundamental","pubTime":"2026-03-26 01:47","pubTimestamp":1774460843,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-ADMA Biologics, Nanobiotix, DraftKingsWorkspace search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Call new","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260325:nL6N40D0LO:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ELVN","IMNN","MAZE","JBLU","NBHC","GNRC","GPRO","CORT","SIDU","ARE","SRPT","BEAM","SLG","PAYX","MPC","BXP","DKNG","TXG","CTAS","PSX","NOV","ADMA","BZAI","LMT","SATL","BG","DINO","CHWY","RGR","DVN","BWXT","TERN","VNO","VLO","KBH","LBRT"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2622006888","title":"Corcept Therapeutics Is Maintained at Buy by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2622006888","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622006888?lang=en_us&edition=fundamental","pubTime":"2026-03-26 01:47","pubTimestamp":1774460820,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/CORT/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 25, 2026 13:47 ET (17:47 GMT)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CORT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622563003","title":"FDA Approves Corcept’s Selective Glucocorticoid Receptor Antagonist Lifyorli™ (Relacorilant) Plus Nab-Paclitaxel for Treatment of Patients With Platinum-Resistant Ovarian Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2622563003","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622563003?lang=en_us&edition=fundamental","pubTime":"2026-03-26 00:43","pubTimestamp":1774456980,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260325:nTUA16XM3R:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","CORT","BK4532","LU1559883803.SGD","LU0566484027.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622393003","title":"Corcept Rockets 48% after FDA Lifyorli Approval — What Does This Mean for CORT Stock?","url":"https://stock-news.laohu8.com/highlight/detail?id=2622393003","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622393003?lang=en_us&edition=fundamental","pubTime":"2026-03-26 00:39","pubTimestamp":1774456763,"startTime":"0","endTime":"0","summary":"Shares in biopharma company Corcept Therapeutics climbed as high as 48% to $48.35 following U.S. approval of Lifyorli for treating certain ovarian-...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/corcept-rockets-48-after-fda-lifyorli-approval-what-does-this-mean-for-cort-stock?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/corcept-rockets-48-after-fda-lifyorli-approval-what-does-this-mean-for-cort-stock?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","LABU","CORT","BK4532","LU1559883803.SGD","LU0566484027.USD","BK4585","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622008757","title":"Corcept Therapeutics price target lowered to $60 from $67 at H.C. Wainwright","url":"https://stock-news.laohu8.com/highlight/detail?id=2622008757","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622008757?lang=en_us&edition=fundamental","pubTime":"2026-03-26 00:10","pubTimestamp":1774455043,"startTime":"0","endTime":"0","summary":"H.C. Wainwright lowered the firm’s price target on Corcept Therapeutics (CORT) to $60 from $67 and keeps a Buy rating on the shares. FDA approval o...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/corcept-therapeutics-price-target-lowered-to-60-from-67-at-h-c-wainwright-thefly-news-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/corcept-therapeutics-price-target-lowered-to-60-from-67-at-h-c-wainwright-thefly-news-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CORT"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.corcept.com","stockEarnings":[{"period":"1week","weight":-0.0137},{"period":"1month","weight":0.2421},{"period":"3month","weight":0.1176},{"period":"6month","weight":-0.4333},{"period":"1year","weight":-0.3812},{"period":"ytd","weight":0.2043}],"compareEarnings":[{"period":"1week","weight":0.036},{"period":"1month","weight":0.0046},{"period":"3month","weight":-0.021},{"period":"6month","weight":0.0405},{"period":"1year","weight":0.2952},{"period":"ytd","weight":-0.0036}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. The company is also developing relacorilant, which is in phase III clinical trial for the treatment of cushing's syndrome; treatment for adrenal cancer and cortisol excess which is in phase 1b clinical trial; treatment for prostate cancer which is in phase II clinical trial; and nab-paclitaxel in combination with relacorilant, which is in phase III clinical trial to treat platinum-resistant ovarian tumors. In addition, it develops dazucorilant, which is in phase II clinical trial for the treatment of amyotrophic lateral sclerosis; miricorilant, which is in phase IIb trial for the treatment of nonalcoholic steatohepatitis; and treatment for antipsychotic induced weight gain that is in phase I trial. The company was incorporated in 1998 and is headquartered in Menlo Park, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.545455,"avgChangeRate":0.022337},{"month":2,"riseRate":0.409091,"avgChangeRate":0.008661},{"month":3,"riseRate":0.772727,"avgChangeRate":0.140734},{"month":4,"riseRate":0.545455,"avgChangeRate":0.000466},{"month":5,"riseRate":0.5,"avgChangeRate":0.00703},{"month":6,"riseRate":0.454545,"avgChangeRate":0.039099},{"month":7,"riseRate":0.454545,"avgChangeRate":-0.006529},{"month":8,"riseRate":0.409091,"avgChangeRate":-0.006283},{"month":9,"riseRate":0.454545,"avgChangeRate":0.062175},{"month":10,"riseRate":0.5,"avgChangeRate":-0.005789},{"month":11,"riseRate":0.5,"avgChangeRate":0.018834},{"month":12,"riseRate":0.409091,"avgChangeRate":0.027449}],"exchange":"NASDAQ","name":"Corcept Therapeutics","nameEN":"Corcept Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.40.0","shortVersion":"4.40.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Corcept Therapeutics(CORT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Corcept Therapeutics(CORT) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Corcept Therapeutics,CORT,Corcept Therapeutics股票,Corcept Therapeutics股票老虎,Corcept Therapeutics股票老虎国际,Corcept Therapeutics行情,Corcept Therapeutics股票行情,Corcept Therapeutics股价,Corcept Therapeutics股市,Corcept Therapeutics股票价格,Corcept Therapeutics股票交易,Corcept Therapeutics股票购买,Corcept Therapeutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Corcept Therapeutics(CORT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Corcept Therapeutics(CORT) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}